



Dear SYMPLIFY Participant,

We are contacting you on behalf of the SYMPLIFY Study Team at University of Oxford to let you know that the study team would like to collect additional follow up data from your centrally held NHS records. This letter explains your options if you do not want any additional data to be collected.

When you agreed to take part in the study you agreed for the study team to be allowed to access your data held centrally by the NHS for up to 12 months after you entered the study. This data is very useful to the study team and we would like to continue to access your data for an additional year. Depending on the results of this additional year's data we may wish to access your data for a third year but we will not access data beyond three years. This will allow us to check if there are any future diagnoses that may help us assess the long-term accuracy of the Galleri™ test

If you do not want us to continue to access your data held centrally by the NHS you have the right to ask us to not to. Asking us not to collect any more data will not affect your NHS treatment in any way. **If you do not want us to continue to collect your NHS data please contact us within 4 weeks of receiving this letter** by emailing [simplify-pc@phc.ox.ac.uk](mailto:simplify-pc@phc.ox.ac.uk) or by writing to:

SYMPLIFY  
Radcliffe Primary Care Building  
Nuffield Department of Primary Care Health Sciences  
Radcliffe Observatory Quarter  
Woodstock Road  
Oxford  
OX2 6GG

In your correspondence, please include details of your date of birth, NHS number and the name of the hospital at which you joined the SYMPLIFY study (if known). You can also call us on 01865 289291 if you prefer.

If you are happy we continue to access your data held by the NHS there is no need for you to do anything further in response to this letter. **If you live in England, do not want us to continue to collect your data, and have already asked for the national data opt out to be applied to your medical records you also do not need to do anything further in response to this letter.** If you do not let us know you wish to opt out, Section 251 support will allow us to access your centrally held NHS record for no longer than a further 2 years.

You can read more about Section 251 and CAG at <https://www.hra.nhs.uk/about-us/committees-and-services/confidentiality-advisory-group/confidential-patient-information-and-regulations/>

You can learn more about how University of Oxford uses your data at <https://www.oncology.ox.ac.uk/clinical-trials/oncology-clinical-trials-office-octo/current-trials/simplify/this-information-is-for-participants-who-joined-the-simplify-study>

The SYMPLIFY main results were published in *Lancet Oncology* in July 2023 and you can read a summary of results at: <https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-a-new-blood-test-to-help-diagnose-cancer-earlier-simplify>.

Future results will be available as they are published at <https://www.oncology.ox.ac.uk/clinical-trials/oncology-clinical-trials-office-octo/current-trials/simplify>

To contact you we have had to process your identifiable data without consent. The processing of identifiable data without consent and outside the direct care team is undertaken with 's251' support from the Health research Authority (HRA) on advice from the Confidentiality Advisory Group (CAG).

If you or a loved one has been impacted by cancer the following listed organisations may be able to offer you help and support: <https://www.cancerresearchuk.org/about-cancer/coping/general-books-links/general-cancer-organisations>

Many thanks again for your invaluable contribution to the success of SYMPLIFY.

Yours faithfully,



Professor Mark Middleton

SYMPLIFY Chief Investigator



Associate Professor Brian Nicholson

SYMPLIFY Lead Investigator